Ensysce Biosciences COO Jeffrey Millard resigns
Ensysce Biosciences, Inc. reported that on July 10, 2026, Chief Operating Officer Jeffrey Millard resigned, effective the same date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Ensysce Biosciences, Inc. reported that on July 10, 2026, Chief Operating Officer Jeffrey Millard resigned, effective the same date. The company received his resignation notice on July 10, 2026.
Ensysce Biosciences’ common stock trades on The Nasdaq Stock Market LLC under the symbol ENSC, and the company is identified as an emerging growth company.
Positive
- None.
Negative
- Chief Operating Officer Jeffrey Millard resigned effective July 10, 2026, removing a key executive from Ensysce Biosciences’ senior management team.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
COO resignation effective date: July 10, 2026
Report date: July 15, 2026
2 metrics
COO resignation effective date
July 10, 2026
Date on which Chief Operating Officer Jeffrey Millard’s resignation became effective
Report date
July 15, 2026
Date Ensysce Biosciences signed the current report regarding the COO resignation
Key Terms
Emerging growth company, Inline XBRL, Exchange Act
3 terms
Emerging growth company regulatory
"Emerging growth company On July 10, 2026, Ensysce Biosciences Inc."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Exchange Act regulatory
"pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What event did Ensysce Biosciences (ENSC) disclose in this 8-K?
Ensysce Biosciences disclosed that Chief Operating Officer Jeffrey Millard resigned, with his resignation notice dated and effective July 10, 2026. This represents a change in the company’s senior leadership and is significant enough to require a current report.
Who resigned from Ensysce Biosciences (ENSC) and what was his role?
The company reported that Jeffrey Millard resigned from his position as Chief Operating Officer. As COO, he was a senior executive responsible for key operational functions, making his departure a material leadership change for Ensysce Biosciences.
When did the resignation of Ensysce Biosciences’ COO become effective?
The resignation of Chief Operating Officer Jeffrey Millard was stated to be effective on July 10, 2026. His written resignation notice was also dated July 10, 2026, so both the notice and effectiveness occurred on the same day.
On which exchange is Ensysce Biosciences (ENSC) listed and under what symbol?
Ensysce Biosciences’ common stock is listed on The Nasdaq Stock Market LLC under the trading symbol ENSC. This listing information confirms the market where the company’s shares are traded and the ticker investors can use.
How does Ensysce Biosciences (ENSC) describe its regulatory status?
Ensysce Biosciences is identified as an emerging growth company. This status, defined under U.S. securities laws, can allow certain reduced reporting requirements and scaled disclosure obligations compared with larger, more established public companies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates